Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05171075 · ClinicalTrials.gov registry record · Phase 3

A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE

A Phase 3 study of Pulmonary Embolism and Venous Thromboembolism, sponsored by Anthos Therapeutics.

Active
Registry status
Phase 3
Development phase
417
Enrollment target
20
Study locations

NCT05171075 is a Phase 3 study of Pulmonary Embolism and Venous Thromboembolism that is active but no longer recruiting, run by Anthos Therapeutics. The registered enrollment target is 417 participants, below the 3,050-participant average among 48 other Pulmonary Embolism trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05171075, a Phase 3 study of Pulmonary Embolism and Venous Thromboembolism, is active but no longer recruiting, sponsored by Anthos Therapeutics.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
417 participants
Enrollment target
20
Study locations

Study Summary

This is a Phase 3, multicenter, open-label, blinded endpoint study to evaluate the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI)/genitourinary (GU) cancer associated VTE (Magnolia)

Conditions Studied

Pulmonary Embolism Venous Thromboembolism Deep Venous Thrombosis

Interventions

  • BIOLOGICAL Abelacimab
  • DRUG Dalteparin

Study Locations (20)

New York

  • Memorial Sloan Kettering Cancer Center-Commack - Commack
  • Memorial Sloan Kettering Cancer Center-West Harrison - Harrison
  • Memorial Sloan Kettering Cancer Center - New York
  • Weill Cornell Medical College - New York

Other

  • LK Wiener Neustadt - Neustadt
  • Medical University of Vienna - Vienna
  • University of Calgary - Calgary
  • Sault Area Hospital - Marie

Ontario

  • Hamilton Health Sciences, Juravinski Hospital and Cancer Centre - Hamilton
  • Ottawa Hospital Research Instituite - Ottawa
  • Ottawa Hospital Research Instituite - Ottawa

New South Wales

  • Blacktown Hospital - Blacktown
  • Westmead Hospital - Westmead

District of Columbia

  • Washington DC VAMC - Washington D.C.

Illinois

  • NorthShore University Health System - Evanston

Missouri

  • Barnes-Jewish Hospital - St Louis

New Jersey

  • Memorial Sloan Kettering Cancer Center-Middletown - Middletown

Trial Details

FieldValue
Enrollment Target 417 participants
Start Date 2022-09-27
Est. Completion 2027-02-28
Phase Phase 3

Sponsor

Anthos Therapeutics

6 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05171075

The ClinicalTrials.gov registry entry for NCT05171075 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 417 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,050-participant average among 48 other Pulmonary Embolism trials with a reported enrollment target (86% lower). The listed sponsor is Anthos Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Pulmonary Embolism appearing as the primary indexed condition, and to 2 interventions - of which Abelacimab is the first listed.

NCT05171075 reports 20 study locations spanning 11 distinct geographic areas - top geographies include New York, Other, Ontario.

Frequently Asked Questions

What is clinical trial NCT05171075 about?

NCT05171075 is a clinical study titled "A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE". This is a Phase 3, multicenter, open-label, blinded endpoint study to evaluate the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI)/genitourinary (GU) cancer associated VTE (Magnolia)

What is the current status of trial NCT05171075?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 417 participants. The study started on 2022-09-27. Estimated completion is 2027-02-28.

What conditions does trial NCT05171075 study?

This clinical trial studies the following conditions: Pulmonary Embolism, Venous Thromboembolism, Deep Venous Thrombosis.

What interventions are being tested in trial NCT05171075?

The interventions under investigation include: Abelacimab (BIOLOGICAL), Dalteparin (DRUG).

Who is sponsoring clinical trial NCT05171075?

This trial is sponsored by Anthos Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05171075 being conducted?

This trial has 20 study locations across District of Columbia, Illinois, Missouri, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pulmonary Embolism

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pulmonary Embolism

All registered trials for this condition

Venous Thromboembolism

All registered trials for this condition

District of Columbia

All trials with a study site in District of Columbia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.